CXCL2 and bacterial infectious disease: Consistent with these findings, our data show that the decrease in CXCL1 and CXCL2 and neutrophil MPO activity during 2° bacterial infection with Sp3 is reversed when the mice are treated with Eritoran prior to bacterial infection.